U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07633756) titled 'A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy' on June 02.
Brief Summary: To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
Study Start Date: Oct. 19, 2026
Study Type: INTERVENTIONAL
Condition:
Phase 1b
Open Label
REC-617
RB1-Negative
Leiomyosarcoma
Intervention:
DRUG: REC617
Given by PO
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....